BTIG Maintains Buy on Connect Biopharma Hldgs, Lowers Price Target to $5

Benzinga Newsdesk www.benzinga.com Negative 58.6%

Neg 58.6% Neu 0% Pos 0%

BTIG analyst Julian Harrison maintains Connect Biopharma Hldgs (NASDAQ:CNTB) with a Buy and lowers the price target from $10 to $5.